The relation between prognosis and lineage specific surface antigen expression on peripheral blood granulocytes and monocytes was studied using monoclonal antibodies and flow cytometry in 37 patients with myelodysplastic syndromes (MDS). Abnormalities in antigen expression were summarised as a score, and cases were divided into low (few abnormalities) and high (many abnormalities) groups. Survival was significantly worse in the "high" group (logrank x2 = 5.793, p = 0X016), this group having a median survival of 31 weeks, compared with more than 67 weeks in the "low" group. No correlations were found between the score and any of the following: peripheral blood platelet and granulocyte count; FAB subtype; bone marrow blast cells and sideroblast count, or erythroid and myeloid progenitor growth. Antigen expression was also studied in six further cases of MDS before and after six weeks of treatment with 1 3-cis retinoic acid (CRA),-20 mg given orally, and a comparison was made with six untreated patients studied before and after a similar time interval. In the treated group 58% of initially abnormal measurements reverted to.normal, compared with 24% in the untreated group. Five of the six treated patients showed a decrease in the score, whereas only two of the six improved in the untreated group. The data indicate that myeloid antigen expression is a useful indicator of prognosis in MDS, and that antigen expression may be affected by treatment.
SUMMARY
The relation between prognosis and lineage specific surface antigen expression on peripheral blood granulocytes and monocytes was studied using monoclonal antibodies and flow cytometry in 37 patients with myelodysplastic syndromes (MDS). Abnormalities in antigen expression were summarised as a score, and cases were divided into low (few abnormalities) and high (many abnormalities) groups. Survival was significantly worse in the "high" group (logrank x2 = 5.793, p = 0X016), this group having a median survival of 31 weeks, compared with more than 67 weeks in the "low" group. No correlations were found between the score and any of the following: peripheral blood platelet and granulocyte count; FAB subtype; bone marrow blast cells and sideroblast count, or erythroid and myeloid progenitor growth. Antigen expression was also studied in six further cases of MDS before and after six weeks of treatment with 1 3-cis retinoic acid (CRA),-20 mg given orally, and a comparison was made with six untreated patients studied before and after a similar time interval. In the treated group 58% of initially abnormal measurements reverted to.normal, compared with 24% in the untreated group. Five of the six treated patients showed a decrease in the score, whereas only two of the six improved in the untreated group. The data indicate that myeloid antigen expression is a useful indicator of prognosis in MDS, and that antigen expression may be affected by treatment.
The myelodysplastic syndromes (MDS) are a group of haemopoietic stem cell disorders with differing manifestations but a common tendency to evolve into acute non-lymphoid leukaemia.' The FAB group proposed a classification of these syndromes based on morphological appearances,2 but it has been suggested that a biological classification of MDS, based on functional abnormalities, may be of greater value.3 Granulocyte function is abnormal in many of these patients, and granulocyte adhesion, superoxide generation, chemotaxis, phagocytosis and intracellular killing capacity are abnormal in 50%. 4 We have previously reported both decreased myeloidmacrophage antigen expression and increased expression of aberrant antigens in about 50% of patients with MDS at the time of presentation.5 We now report the relation between myeloid-macrophage surface antigen abnormalities and prognosis, and the changes in antigen expression induced by treatment. 1 3-cis retinoic acid (CRA) inhibits the development of papillomas induced by carcinogens in mice6 and the malignant transformation of cultured cell lines.7
Accepted for publication 22 Stained cell suspensions were analysed in a FACS III number of abnormal measurements cell sorter (Becton Dickinson) using a 4 watt argon total number of measurements x 100 
Results

PROGNOSTIC RELEVANCE OF SURFACE ANTIGEN SCORE
The median value of the score (SAS) in the 37 cases for whom sufficient data were available was 30%.
Cases were divided into a low (<30%) and a high (> 30%) group, and table 2 shows the proportion of deaths and leukaemic transformations in each group. The difference in the rate of leukaemic transformations between the two groups was highly significant (p = 0-014, Fisher's exact test). Table 2 also shows the mean survival times at 65-148 weeks and the 75% survival times for each group. The median survival was 31 weeks in the high scoring group, but was not reached at 67 weeks in the low scoring group. The figure shows Kaplan-Meier survival curves for each group and the significant difference in survival (logrank x2 = 5-793, p = 0-016).
RELATION BETWEEN SURFACE ANTIGEN SCORE AND OTHER PERIPHERAL BLOOD AND BONE MARROW ABNORMALITIES
No correlation was found between the score and peripheral blood platelet or granulocyte count, FAB subtype, bone marrow blast cells, sideroblast count or erythroid and myeloid progenitor growths. A weak negative correlation was observed with the peripheral blood haemoglobin (rs = -0 44, p = 0.006).
,ZI1.00-_ Those cases with a high score may have progressed further along the premalignant pathway, and so tend to have a shorter survival. There is little correlation, however, between the score and other prognostic variables such as the bone marrow blast number and peripheral blood cytopenia, both of which tend to change adversely during the evolution of the disease. Though a weak correlation is seen with peripheral blood haemoglobin concentration, this is difficult to interpret as some patients depend on transfusions. Surface antigen expression seems to be an independent prognostic variable.
The surface antigen score is closely related to subsequent leukaemic transformation. This is independent of the association with short survival, as many patients died in the absence of leukaemic transformation (table 2) , often the case in this condition. 31 The present association of high score and subsequent leukaemic transformation confirms the observations of Hokland etal,26 who showed that cases with abnormal bone marrow mononuclear cell My7 expression had an increased tendency to evolve to RAEB and acute myeloid leukaemia.
CRA has been shown to induce changes in antigen expression932 and surface glycoproteins on HL60 cells.33 Increases in antigens associated with maturing myeloid cells have been shown on acute nonlymphoid leukaemia blasts in vitro. 34 The present data show improvement in abnormal surface antigen expression on peripheral granulocytes and monocytes from some myelodysplastic patients treated with CRA. Serum concentration in patients treated with 20 mg CRA orally daily are about 1 pmol/l. 5 At this concentration both differentiation promoting and antiproliferative effects may be shown in vitro in normal CFU-GM10 35 and some leukaemic blasts,"1 36 and an antiproliferative effect has been shown on CFU-GM in MDS. 12 The effect of CRA on surface antigen expression shown here may be mediated by inducing differentiation of normal progenitors, decreasing proliferation of abnormal progenitors, or a combination of these effects.
